DEA's Philadelphia Division conducted a review of laboratory analyzed drug seizures for Pennsylvania. The results of analyzing this data formed the basis for estimating the level of drugs present in Pennsylvania and highlights trends in drug availability.

The flow of fentanyl into the United States in 2019 is more diverse compared to the start of the fentanyl crisis in 2014, with new source countries and new transit countries emerging as significant trafficking nodes. This is exacerbating the already multi-faceted fentanyl crisis by introducing additional source countries into...

The DEA New Orleans Division conducted a five-year review of the data on synthetic substances reported in the National Forensic Laboratory Information System for their area of responsibility. The findings revealed that Louisiana submitted the majority of reports for synthetic cannabinoid substance and synthetic cathinones substance for 2013 to 2017...

The 2019 National Drug Threat Assessment (NDTA) is a comprehensive strategic assessment of the threat posed to the United States by domestic and international drug trafficking and the abuse of both licit and illicit drugs. The report combines federal, state, local, and tribal law enforcement reporting; public health data; open...

The vast majority of drugs entering Chicago and the surrounding area, including fentanyl and fentanyl-related substances (FRS), heroin, cocaine, and methamphetamine, continue to be smuggled across the United States–Mexico border. Availability and abuse of these drugs is high, with opioids being the most prevalent in major cities and methamphetamine in...

The Fentanyl Signature Profiling Program (FSPP) performs in-depth chemical analyses on fentanyl and fentanyl-related exhibits obtained from seizures made throughout the United States. This report details the results and conclusions derived from these analyses that are reported on a quarterly basis. FSPP data is not intended to reflect U.S. market...

The Drug Enforcement Administration (DEA) Chicago Field Division (CFD) conducted a study of all exhibits containing fentanyl and/or fentanyl-related substances (FRS) acquired within the CFD’s area of responsibility (AOR) between fiscal year (FY) 2015 and FY 2019 up to May 30, 2019. The CFD AOR includes the States of Illinois...

The phenomenon of drug overdose death has grown steadily worse in the United States during most of the 21st century and has been skyrocketing since 2013 and the introduction of illicitly manufactured fentanyl-related substances into the domestic drug market...

Since 2014, the Drug Enforcement Administration (DEA) Philadelphia Division Intelligence Program (PDIP) has annually collected and analyzed data and disseminated perceived trends and key findings that concern drug-related overdose deaths in Pennsylvania. This analysis has informed a multi-disciplinary audience relating to the drugs, populations, and geographic areas of greatest concern...

The Drug Enforcement Administration (DEA) Philadelphia Division’s Intelligence Program (PDIP) reviewed a set of data indicators for the years 2015-2018 to assess the current prescription opioid threat in Pennsylvania. Analysis revealed that a positive change in the prescription opioid threat may be underway...